Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Top Cited Papers
Open Access
- 1 July 2008
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 372 (9634) , 216-223
- https://doi.org/10.1016/s0140-6736(08)61075-2
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Absence of β-Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body DementiaArchives of Neurology, 2007
- Aβ Species Removal After Aβ42ImmunizationJournal of Neuropathology and Experimental Neurology, 2006
- Has the Amyloid Cascade Hypothesis for Alzheimers Disease been Proved?Current Alzheimer Research, 2006
- Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trialNeurology, 2005
- Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with ADNeurology, 2005
- Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunizationNeurology, 2003
- Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's DiseaseNeuron, 2003
- Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case reportNature Medicine, 2003
- Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's diseaseNature, 2000
- Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouseNature, 1999